Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of dollars, reveals research published ...
Dec 21, 2025
0
33
Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body radiation therapy (SBRT) ...
Sep 26, 2025
0
21
A new policy review published in The Lancet Oncology and led by Ian Tannock and Madeline Pe, together with an international team of oncologists, statisticians, patients and patient-reported outcomes (PRO) experts from Common ...
Sep 3, 2025
0
12
Scientists say they have worked out a machine learning method with the ability to provide close to precise survival estimates of patients afflicted with prostate adenocarcinoma, which is by far the most common type of prostatic ...
Jun 2, 2025
0
17
Marital status significantly impacts survival rates for patients with colorectal cancer, according to a new study co-authored by a Fox Chase Cancer Center researcher that was presented today at the American Society of Clinical ...
Jun 2, 2025
0
13
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according ...
May 30, 2025
0
21
Fragmented care—receiving medical treatment at more than one facility—has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as cancer type and treatment venue.
May 13, 2025
0
8
Eyes may be the window to the soul, but a person's biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm called "FaceAge" that uses ...
May 8, 2025
0
120
Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in Renal Cell Carcinoma) study underscore the critical role of tumor size reduction in improving survival ...
Feb 20, 2025
0
23
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall ...
Feb 19, 2025
0
18
